JB/CALL/ROCHE GS/225/0.025/20.09.24 Stock

ROGTJB

CH1298679924

Market Closed - Swiss Exchange 11:15:01 2024-05-10 EDT
0.29 ^CHF	+20.83%

Current month	+26.09%
1 month	-3.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ROCHE HOLDING AG

Chart JB/CALL/ROCHE GS/225/0.025/20.09.24

Latest news about ROCHE HOLDING AG

Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	05-10	MT
Enable Injections, Inc. Announces Collaboration with Roche to Develop and Commercialize Combination of the enFuse Technology with Specific Roche Development Programs	05-07	CI
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating	05-06	ZD
Swiss Equities Close in Red Amid Inflation Spotlight	04-29	MT

More news

Quotes 5-day view

Date	Price	Change	Volume
24-05-10	0.29	+20.83%	73,500
24-05-08	0.24	+9.09%	5,400
24-05-07	0.22	+10.00%	3,500
24-05-06	0.2	+11.11%	4,900
24-05-03	0.18	+12.50%	24,800

Delayed Quote Swiss Exchange

Last update May 10, 2024 at 11:15 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ROCHE HOLDING AG
Issuer	Bank Julius Bär
	ROGTJB
ISIN	CH1298679924
Date issued	2023-11-01
Strike	225 CHF
Maturity	2024-09-20 (131 Days)
Parity	40 : 1
Emission price	0.52 CHF
Emission volume	N/A
Settlement	both
Currency	CHF

Technical Indicators

Highest since issue	0.83 CHF
Lowest since issue	0.15 CHF
Spread	0.01 CHF
Spread %	3.45%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

More about the company

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Consensus: Roche Holding AG

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

225.1 CHF

Average target price

279.4 CHF

Spread / Average Target

+24.12%

Consensus